BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36713582)

  • 1. Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile.
    Brown K; Jenkins LMM; Crooks DR; Surman DR; Mazur SJ; Xu Y; Arimilli BS; Yang Y; Lane AN; Fan TW; Schrump DS; Linehan WM; Ripley RT; Appella E
    Front Oncol; 2022; 12():1094210. PubMed ID: 36713582
    [No Abstract]   [Full Text] [Related]  

  • 2. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
    Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
    Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells.
    Zhang S; Zhou L; El-Deiry WS
    Mol Cancer Res; 2022 Apr; 20(4):622-636. PubMed ID: 34992144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
    Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
    Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of p53 function on the metabolic activation of the carcinogenic air pollutant 3-nitrobenzanthrone and its metabolites 3-aminobenzanthrone and N-hydroxy-3-aminobenzanthrone in human cells.
    Wohak LE; Baranski AC; Krais AM; Schmeiser HH; Phillips DH; Arlt VM
    Mutagenesis; 2018 Oct; 33(4):311-321. PubMed ID: 30215795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU
    Gao X; Zheng X; Zhang Y; Dong L; Sun L; Zhao N; Ding C; Ma Z; Wang Y
    Front Cell Dev Biol; 2021; 9():788331. PubMed ID: 35071232
    [No Abstract]   [Full Text] [Related]  

  • 8. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells.
    Yoshikawa K; Hamada J; Tada M; Kameyama T; Nakagawa K; Suzuki Y; Ikawa M; Hassan NM; Kitagawa Y; Moriuchi T
    Biomed Res; 2010 Dec; 31(6):401-11. PubMed ID: 21187651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
    Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
    Front Oncol; 2021; 11():642603. PubMed ID: 34178628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing.
    Xu A; Zhou R; Tu J; Huo Z; Zhu D; Wang D; Gingold JA; Mata H; Rao PH; Liu M; Mohamed AMT; Kong CSL; Jewell BE; Xia W; Zhao R; Hung MC; Lee DF
    Stem Cell Res; 2018 May; 29():215-219. PubMed ID: 29730572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.
    Dominijanni A; Gmeiner WH
    Cancer Drug Resist; 2018; 1():48-58. PubMed ID: 30613833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
    Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
    J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.
    Schilling T; Kairat A; Melino G; Krammer PH; Stremmel W; Oren M; Müller M
    Biochem Biophys Res Commun; 2010 Apr; 394(3):817-23. PubMed ID: 20233581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.
    Aggarwal M; Saxena R; Sinclair E; Fu Y; Jacobs A; Dyba M; Wang X; Cruz I; Berry D; Kallakury B; Mueller SC; Agostino SD; Blandino G; Avantaggiati ML; Chung FL
    Cell Death Differ; 2016 Oct; 23(10):1615-27. PubMed ID: 27258787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common gain of function of p53 cancer mutants in inducing genetic instability.
    Liu DP; Song H; Xu Y
    Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (
    Balasundaram A; Doss CGP
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
    Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
    Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
    Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.